3Q EARNINGS: US order helps Amgen beat Wall Street estimates, Kyprolis sales stall
This article was originally published in Scrip
Executive Summary
Amgen said it beat profit estimates for the third quarter thanks to a large US government order for a single drug, but sales of its newly acquired cancer therapy Kyprolis were light.